Transgenic Mouse Models of Cardiovascular Function and Disease

  • W. J. Koch
  • B. C. Blaxall
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 159)

Abstract

Transgenic mouse technology, coupled with cardiac-specific promoters and complex measurements of murine myocardial function and hemodynamics, have played an important role in expanding our knowledge regarding adrenergic receptors and downstream components of their signal transduction cascade in both normal and diseased heart function. Herein we discuss the results and implications of overexpression or ablation of several adrenergic receptors and/or downstream effectors in their G protein signaling pathway to further delineate their potential roles in both normal and diseased heart function. Finally, we discuss a number of mouse models of heart failure, and how they can act as important “in vivo reaction vessels” to identify and test specific genes/hypotheses which may lead to novel therapeutics for heart disease.

Keywords

Heart failure Adrenergic receptor G protein Kinase Signaling Transgenic Knockout 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams, J. W., Sakata, Y., Davis, M. G., Sah, V. P., Wang, Y., Liggett, S. B., Chien, K. R., Brown, J. H., and Dorn, G. W., 2nd (1998). Enhanced Gαlq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95, 10140–5.PubMedCrossRefGoogle Scholar
  2. Ahlquist, R. (1948). A study of the adrenotropic receptors. Am J Physiol 153, 586–600.PubMedGoogle Scholar
  3. Akhter, S. A., Milano, C. A., Shotwell, K. F., Cho, M. C., Rockman, H. A., Lefkowitz, R. J., and Koch, W. J. (1997). Transgenic mice with cardiac overexpression of α1B-adrenergic receptors. In vivo α1-adrenergic receptor-mediated regulation of β-adrenergic signaling. J Biol Chem 272, 21253–9.PubMedCrossRefGoogle Scholar
  4. Akhter, S. A., Skaer, C. A., Kypson, A. P., McDonald, P. H., Peppel, K. C., Glower, D. D., Lefkowitz, R. J., and Koch, W. J. (1997). Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci USA 94, 12100–5.PubMedCrossRefGoogle Scholar
  5. Akhter, S. A., Eckhart, A. D., Rockman, H. A., Shotwell, K., Lefkowitz, R. J., and Koch, W. J. (1999). In vivo inhibition of elevated myocardial β-adrenergic receptor kinase activity in hybrid transgenic mice restores normal β-adrenergic signaling and function [see comments]. Circulation 100, 648–53.PubMedCrossRefGoogle Scholar
  6. Anderson, K. M., Eckhart, A. D., Willette, R. N., and Koch, W. J. (1999). The myocardial β-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. Hypertension 33, 402–7.PubMedCrossRefGoogle Scholar
  7. Anversa, P., Loud, A. V., Levicky, V., and Guideri, G. (1985). Left ventricular failure induced by myocardial infarction. I. Myocyte hypertrophy. Am J Physiol 248, H876–82.PubMedGoogle Scholar
  8. Arber, S., Hunter, J. J., Ross, J., Jr., Hongo, M., Sansig, G., Borg, J., Perriard, J. C., Chien, K. R., and Caroni, P. (1997). MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88, 393–403.PubMedCrossRefGoogle Scholar
  9. Bisognano, J. D., Weinberger, H. D., Bohlmeyer, T. J., Pende, A., Raynolds, M. V., Sastravaha, A., Roden, R., Asano, K., Blaxall, B. C., Wu, S. C., Communal, C., Singh, K., Colucci, W., Bristow, M. R., and Port, D. J. (2000). Myocardial-directed overexpression of the human β1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 32, 817–30.PubMedCrossRefGoogle Scholar
  10. Blaxall, B. C., Lefkowitz, R. J., and Koch, W J. (2000). Differential patterns of gene expression in the development and rescue of mouse heart failure. Circulation 102, II–30.Google Scholar
  11. Bohm, M., Moll, M., Schmid, B., Paul, M., Ganten, D., Castellano, M., and Erdmann, E. (1994). β-adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats. Hypertension 24, 653–62.PubMedCrossRefGoogle Scholar
  12. Bristow, M. R., Ginsburg, R., Minobe, W., Cubicciotti, R. S., Sageman, W. S., Lurie, K., Billingham, M. E., Harrison, D. C., and Stinson, E. B. (1982). Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl JMed 307, 205–11.CrossRefGoogle Scholar
  13. Bristow, M. R., Hershberger, R. E., Port, J. D., Minobe, W., and Rasmussen, R. (1989). β1-and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 35, 295–303.PubMedGoogle Scholar
  14. Bristow, M. R., Hershberger, R. E., Port, J. D., Gilbert, E. M., Sandoval, A., Rasmussen, R., Cates, A. E., and Feldman, A. M. (1990). β-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82, I12–25.PubMedCrossRefGoogle Scholar
  15. Brodde, O. E. (1993). β-adrenoceptors in cardiac disease. Pharmacol Ther 60, 405–30.PubMedCrossRefGoogle Scholar
  16. Caron, M. G., and Lefkowitz, R. J. (1993). Catecholamine receptors: structure, function, and regulation. Recent Prog Horm Res 48, 277–90.PubMedGoogle Scholar
  17. Cavalli, A., Lattion, A. L., Hummler, E., Nenniger, M., Pedrazzini, T., Aubert, J. F., Michel, M. C., Yang, M., Lembo, G., Vecchione, C., Mostardini, M., Schmidt, A., Beermann, F., and Cotecchia, S. (1997). Decreased blood pressure response in mice deficient of the α1b-adrenergic receptor. Proc Natl Acad Sci USA 94, 11589–94.PubMedCrossRefGoogle Scholar
  18. Cho, M. C., Rapacciuolo, A., Koch, W. J., Kobayashi, Y., Jones, L. R., and Rockman, H. A. (1999). Defective β-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J Biol Chem 274, 22251–6.PubMedCrossRefGoogle Scholar
  19. Choi, D. J., Koch, W. J., Hunter, J. J., and Rockman, H. A. (1997). Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergic receptor kinase. J Biol Chem 272, 17223–9.PubMedCrossRefGoogle Scholar
  20. Chruscinski, A. J., Rohrer, D. K., Schauble, E., Desai, K. H., Bernstein, D., and Kobilka, B. K. (1999). Targeted disruption of the β2 adrenergic receptor gene. J Biol Chem 274, 16694–700.PubMedCrossRefGoogle Scholar
  21. Chuang, T. T., Le Vine, H., 3rd, and De Blasi, A. (1995). Phosphorylation and activation of β-adrenergic receptor kinase by protein kinase C. J Biol Chem 270, 18660–5.PubMedCrossRefGoogle Scholar
  22. CIBIS-II (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9–13.CrossRefGoogle Scholar
  23. Clapham, D. E., and Neer, E. J. (1997). G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 37, 167–203.PubMedCrossRefGoogle Scholar
  24. Communal, C., Singh, K., Sawyer, D. B., and Colucci, W. S. (1999). Opposing effects of β1-and β2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100, 2210–2.PubMedCrossRefGoogle Scholar
  25. Daaka, Y., Luttrell, L. M., and Lefkowitz, R. J. (1997). Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88–91.PubMedCrossRefGoogle Scholar
  26. D’Angelo, D. D., Sakata, Y., Lorenz, J. N., Boivin, G. P., Walsh, R. A., Liggett, S. B., and Dorn, G. W., 2nd (1997). Transgenic Gaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 94, 8121–6.PubMedCrossRefGoogle Scholar
  27. Dorn, G. W., 2nd, Tepe, N. M., Lorenz, J. N., Koch, W. J., and Liggett, S. B. (1999). Low-and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc Natl Acad Sci USA 96, 6400–5.PubMedCrossRefGoogle Scholar
  28. Dostal, D. E., and Baker, K. M. (1998). Angiotensin and endothelin: messengers that couple ventricular stretch to the Na+/H+ exchanger and cardiac hypertrophy. Circ Res 83, 870–3.PubMedCrossRefGoogle Scholar
  29. Eckhart, A. D., Duncan, S. J., Penn, R. B., Benovic, J. L., Lefkowitz, R. J., and Koch, W. J. (2000). Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res 86, 43–50.PubMedCrossRefGoogle Scholar
  30. Engelhardt, S., Hein, L., Wiesmann, F., and Lohse, M. J. (1999). Progressive hypertrophy and heart failure in α1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96, 7059–64.PubMedCrossRefGoogle Scholar
  31. Exton, J. H. (1985). Mechanisms involved in α-adrenergic phenomena. Am J Physiol 248, E633–47.PubMedGoogle Scholar
  32. Feldman, A. M., Cates, A. E., Veazey, W. B., Hershberger, R. E., Bristow, M. R., Baughman, K. L., Baumgartner, W. A., and Van Dop, C. (1988). Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82, 189–97.PubMedCrossRefGoogle Scholar
  33. Freeman, K., Colon-Rivera, C., Olsson, M. C., Moore, R. L., Weinberger, H. D., Grupp, I. L., Vikstrom, K. L., Iaccarino, G., Koch, W J., and Leinwand, L. A. (1999). Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene. Am J Physiol Heart Circ Physiol 280, H151–9.Google Scholar
  34. Freeman, K., Lerman, I., Kranias, E. G., Bohlmeyer, T., Bristow, M. R., Lefkowitz, R. J., Iaccarino, G., Koch, W. J., and Leinwand, L. A. (2001). Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 107, 967–74.PubMedCrossRefGoogle Scholar
  35. Gao, M., Ping, P., Post, S., Insel, P. A., Tang, R., and Hammond, H. K. (1998). Increased expression of adenylylcyclase type VI proportionately increases β-adrenergic receptor-stimulated production of cAMP in neonatal rat cardiac myocytes. Proc Natl Acad Sci USA 95, 1038–43.PubMedCrossRefGoogle Scholar
  36. Gauthier, C., Tavernier, G., Charpentier, F., Langin, D., and Le Marec, H. (1996). Functional β3-adrenoceptor in the human heart. J Clin Invest 98, 556–62.PubMedCrossRefGoogle Scholar
  37. Gidh-Jain, M., Huang, B., Jain, P., Gick, G., and El-Sherif, N. (1998). Alterations in cardiac gene expression during ventricular remodeling following experimental myocardial infarction. J Mol Cell Cardiol 30, 627–37.PubMedCrossRefGoogle Scholar
  38. Grossman, W., Jones, D., and McLaurin, L. P. (1975). Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56, 56–64.PubMedCrossRefGoogle Scholar
  39. Grupp, I. L., Lorenz, J. N., Walsh, R. A., Boivin, G. P., and Rindt, H. (1998). Overexpression of α1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Am J Physiol 275, H1338–50.PubMedGoogle Scholar
  40. Harding, S. E., MacLeod, K. T., Davies, C. H., Wynne, D. G., and Poole-Wilson, P. A. (1995). Abnormalities of the myocytes in ischaemic cardiomyopathy. Eur Heart J 16 Suppl I, 74–81.PubMedCrossRefGoogle Scholar
  41. Harding, V. B., Jones, L. R., Lefkowitz, R. J., Koch, W. J., and Rockman, H. A. (2001). Cardiac βARK1 inhibition prolongs survival and augments yö-blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA 98, 5809–14.PubMedCrossRefGoogle Scholar
  42. Harrison, S. N., Autelitano, D. J., Wang, B. H., Milano, C., Du, X. J., and Woodcock, E. A. (1998). Reduced reperfusion-induced Ins(1,4,5)P3 generation and arrhythmias in hearts expressing constitutively active α1B-adrenergic receptors. Circ Res 83, 1232–40.PubMedCrossRefGoogle Scholar
  43. Hoffman, B. B., and Lefkowitz, R. J. (1996). In Goodman and Gilman’s The Pharmacological Basis of Therapeutics, J. G. Hardman, A. G. Gilman and L. E. Limbird, eds. (New York: McGraw-Hill), pp. 199–248.Google Scholar
  44. Huang, W. Y., Aramburu, J., Douglas, P. S., and Izumo, S. (2000). Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat Med 6, 482–3.PubMedCrossRefGoogle Scholar
  45. Iaccarino, G., Dolber, P. C., Lefkowitz, R. J., and Koch, W. J. (1999). β-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by β-but not α1-adrenergic stimulation. Hypertension 33, 396–401.PubMedCrossRefGoogle Scholar
  46. Iaccarino, G., Keys, J. R., Rapacciuolo, A., Shotwell, K. F., Lefkowitz, R. J., Rockman, H. A., and Koch, W J. (2001). Regulation of myocardial βARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing α1B-adrenergic receptors. J Am Coll Cardiol 38, 534–40.PubMedCrossRefGoogle Scholar
  47. Iaccarino, G., Rockman, H. A., Shotwell, K. F., Tomhave, E. D., and Koch, W. J. (1998). Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Am J Physiol 275, H1298–306.PubMedGoogle Scholar
  48. Iaccarino, G., Tomhave, E. D., Lefkowitz, R. J., and Koch, W J. (1998). Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 98, 1783–9.PubMedCrossRefGoogle Scholar
  49. Inglese, J., Freedman, N. J., Koch, W J., and Lefkowitz, R. J. (1993). Structure and mechanism of the G protein-coupled receptor kinases. J Biol Chem 268, 23735–8.PubMedGoogle Scholar
  50. Ishii, K., Chen, J., Ishii, M., Koch, W. J., Freedman, N. J., Lefkowitz, R. J., and Coughlin, S. R. (1994). Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases. J Biol Chem 269, 1125–30.PubMedGoogle Scholar
  51. Iwase, M., Bishop, S. P., Uechi, M., Vatner, D. E., Shannon, R. P., Kudej, R. K., Wight, D. C., Wagner, T. E., Ishikawa, Y., Homcy, C. J., and Vatner, S. F. (1996). Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsα overexpression. Circ Res 78, 517–24.PubMedCrossRefGoogle Scholar
  52. Iwase, M., Uechi, M., Vatner, D. E., Asai, K., Shannon, R. P., Kudej, R. K., Wagner, T. E., Wight, D. C., Patrick, T. A., Ishikawa, Y., Homcy, C. J., and Vatner, S. R (1997). Cardiomyopathy induced by cardiac Gsa overexpression. Am J Physiol 272, H585–9.PubMedGoogle Scholar
  53. Jaber, M., Koch, W. J., Rockman, H., Smith, B., Bond, R. A., Sulik, K. K., Ross, J., Jr., Lefkowitz, R. J., Caron, M. G., and Giros, B. (1996). Essential role of β-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci USA 93, 12974–9.PubMedCrossRefGoogle Scholar
  54. Ju, H., Zhao, S., Tappia, P. S., Panagia, V., and Dixon, I. M. (1998). Expression of Gqα and PLC-b in scar and border tissue in heart failure due to myocardial infarction. Circulation 97, 892–9.PubMedCrossRefGoogle Scholar
  55. Knowlton, K. U., Michel, M. C., Itani, M., Shubeita, H. E., Ishihara, K., Brown, J. H., and Chien, K. R. (1993). The α1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 268, 15374–80.PubMedGoogle Scholar
  56. Koch, W. J., Inglese, J., Stone, W. C., and Lefkowitz, R. J. (1993). The binding site for the βγ subunits of heterotrimeric G proteins on the β-adrenergic receptor kinase. J Biol Chem 268, 8256–60.PubMedGoogle Scholar
  57. Koch, W. J., Rockman, H. A., Samama, P., Hamilton, R. A., Bond, R. A., Milano, C. A., and Lefkowitz, R. J. (1995). Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a bARK inhibitor. Science 268, 1350–3.PubMedCrossRefGoogle Scholar
  58. Koch, W. J., Lefkowitz, R. J., and Rockman, H. A. (2000). Functional consequences of altering myocardial adrenergic receptor signaling. Annu Rev Physiol 62, 237–60.PubMedCrossRefGoogle Scholar
  59. Korzick, D. H., Xiao, R. P., Ziman, B. D., Koch, W. J., Lefkowitz, R. J., and Lakatta, E. G. (1997). Transgenic manipulation of β-adrenergic receptor kinase modifies cardiac myocyte contraction to norepinephrine. Am J Physiol 272, H590–6.PubMedGoogle Scholar
  60. Laporte, S. A., Oakley, R. H., Holt, J. A., Barak, L. S., and Caron, M. G. (2000). The interaction of β-arrestin with the AP-2 adaptor is required for the clustering of β2-adrenergic receptor into clathrin-coated pits. J Biol Chem 275, 23120–6.PubMedCrossRefGoogle Scholar
  61. Lefkowitz, R. J. (1998). G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 273, 18677–80.PubMedCrossRefGoogle Scholar
  62. Lemire, I., Allen, B. G., Rindt, H., and Hebert, T. E. (1998). Cardiac-specific overexpression of α 1 BAR regulates βAR activity via molecular crosstalk. J Mol Cell Cardiol 30, 1827–39.PubMedCrossRefGoogle Scholar
  63. Lemire, I., Ducharme, A., Tardif, J. C., Poulin, F., Jones, L. R., Allen, B. G., Hebert, T. E., and Rindt, H. (2001). Cardiac-directed overexpression of wild-type α1B-adrenergic receptor induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 281, H931–8.PubMedGoogle Scholar
  64. Liggett, S. B., Tepe, N. M., Lorenz, J. N., Canning, A. M., Jantz, T. D., Mitarai, S., Yatani, A., and Dorn, G. W., 2nd (2000). Early and delayed consequences of β2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101, 1707–14.PubMedCrossRefGoogle Scholar
  65. Lorell, B. H. (1997). Transition from hypertrophy to failure. Circulation 96, 3824–7.PubMedGoogle Scholar
  66. Manning, B. S., Shotwell, K., Mao, L., Rockman, H. A., and Koch, W. J. (2000). Physiological induction of a β-adrenergic receptor kinase inhibitor transgene preserves β-ad-renergic responsiveness in pressure-overload cardiac hypertrophy. Circulation 102, 2751–7.PubMedCrossRefGoogle Scholar
  67. Maurice, J. P., Shah, A. S., Kypson, A. P., Hata, J. A., White, D. C., Glower, D. D., and Koch, W. J. (1999). Molecular β-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol 276, H1853–60.PubMedGoogle Scholar
  68. Mende, U., Kagen, A., Cohen, A., Aramburu, J., Schoen, F. J., and Neer, E. J. (1998). Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 95, 13893–8.PubMedCrossRefGoogle Scholar
  69. Mende, U., Semsarian, C., Martins, D. C., Kagen, A., Duffy, C., Schoen, F. J., and Neer, E. J. (2001). Dilated cardiomyopathy in two transgenic mouse lines expressing activated G protein aq: lack of correlation between phospholipase C activation and the phenotype. J Mol Cell Cardiol 33, 1477–91.PubMedCrossRefGoogle Scholar
  70. MERIT-HF (1999). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/ XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001–7.CrossRefGoogle Scholar
  71. Milano, C. A., Allen, L. F., Rockman, H. A., Dolber, P. C., McMinn, T. R., Chien, K. R., Johnson, T. D., Bond, R. A., and Lefkowitz, R. J. (1994). Enhanced myocardial function in transgenic mice overexpressing the β2-adrenergic receptor. Science 264, 582–6.PubMedCrossRefGoogle Scholar
  72. Milano, C. A., Dolber, P. C., Rockman, H. A., Bond, R. A., Venable, M. E., Allen, L. F., and Lefkowitz, R. J. (1994). Myocardial expression of a constitutively active α1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91, 10109–13.PubMedCrossRefGoogle Scholar
  73. Minamisawa, S., Hoshijima, M., Chu, G., Ward, C. A., Frank, K., Gu, Y., Martone, M. E., Wang, Y., Ross, J., Jr., Kranias, E. G., Giles, W. R., and Chien, K. R. (1999). Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313–22.PubMedCrossRefGoogle Scholar
  74. Naga Prasad, S. V., Barak, L. S., Rapacciuolo, A., Caron, M. G., and Rockman, H. A. (2001). Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by β-adrenergic receptor kinase 1. A role in receptor sequestration. J Biol Chem 276, 18953–9.PubMedCrossRefGoogle Scholar
  75. Ostrom, R. S., Post, S. R., and Insel, P. A. (2000). Stoichiometry and compartmentation in G protein-coupled receptor signaling: implications for therapeutic interventions involving G(s). J Pharmacol Exp Ther 294, 407–12.PubMedGoogle Scholar
  76. Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., and Shusterman, N. H. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334, 1349–55.PubMedCrossRefGoogle Scholar
  77. Packer, M., Coats, A. J., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., Schultz, M. K., and DeMets, D. L. (2001). Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344, 1651–8.PubMedCrossRefGoogle Scholar
  78. Ping, P., Anzai, T., Gao, M., and Hammond, H. K. (1997). Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol 273, H707–17.PubMedGoogle Scholar
  79. Pitcher, J. A., Inglese, J., Higgins, J. B., Arriza, J. L., Casey, P. J., Kim, C., Benovic, J. L., Kwatra, M. M., Caron, M. G., and Lefkowitz, R. J. (1992). Role of beta gamma subunits of G proteins in targeting the β-adrenergic receptor kinase to membranebound receptors. Science 257, 1264–7.PubMedCrossRefGoogle Scholar
  80. Pitcher, J. A., Freedman, N. J., and Lefkowitz, R. J. (1998). G protein-coupled receptor kinases. Annu Rev Biochem 67, 653–92.PubMedCrossRefGoogle Scholar
  81. Redfern, C. H., Degtyarev, M. Y., Kwa, A. T., Salomonis, N., Cotte, N., Nanevicz, T., Fidelman, N., Desai, K., Vranizan, K., Lee, E. K., Coward, P., Shah, N., Warrington, J. A., Fishman, G. I., Bernstein, D., Baker, A. J., and Conklin, B. R. (2000). Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc Natl Acad Sci USA 97, 4826–31.PubMedCrossRefGoogle Scholar
  82. Rockman, H. A., Choi, D. J., Rahman, N. U., Akhter, S. A., Lefkowitz, R. J., and Koch, W. J. (1996). Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA 93, 9954–9.PubMedCrossRefGoogle Scholar
  83. Rockman, H. A., Hamilton, R. A., Jones, L. R., Milano, C. A., Mao, L., and Lefkowitz, R. J. (1996). Enhanced myocardial relaxation in vivo in transgenic mice overexpressing the β2-adrenergic receptor is associated with reduced phospholamban protein. J Clin Invest 97, 1618–23.PubMedCrossRefGoogle Scholar
  84. Rockman, H. A., Chien, K. R., Choi, D. J., Iaccarino, G., Hunter, J. J., Ross, J., Jr., Lefkowitz, R. J., and Koch, W. J. (1998). Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 95, 7000–5.PubMedCrossRefGoogle Scholar
  85. Rockman, H. A., Choi, D. J., Akhter, S. A., Jaber, M., Giros, B., Lefkowitz, R. J., Caron, M. G., and Koch, W. J. (1998). Control of myocardial contractile function by the level of β-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 273, 18180–4.PubMedCrossRefGoogle Scholar
  86. Rockman, H. A., Koch, W. J., and Lefkowitz, R. J. (2002). Seven-transmembrane-spanning receptors and heart function. Nature 415, 206–12.PubMedCrossRefGoogle Scholar
  87. Rohrer, D. K. (1998). Physiological consequences of β-adrenergic receptor disruption. J Mol Med 76, 764–72.PubMedCrossRefGoogle Scholar
  88. Rossant, J. (1996). Mouse mutants and cardiac development: new molecular insights into cardiogenesis. Circ Res 78, 349–53.PubMedCrossRefGoogle Scholar
  89. Roth, D. M., Gao, M. H., Lai, N. C., Drumm, J., Dalton, N., Zhou, J. Y., Zhu, J., Entrikin, D., and Hammond, H. K. (1999). Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 99, 3099–102.PubMedCrossRefGoogle Scholar
  90. Sakata, Y., Hoit, B. D., Liggett, S. B., Walsh, R. A., and Dorn, G. W., 2nd (1998). Decompensation of pressure-overload hypertrophy in Gαq-overexpressing mice. Circulation 97, 1488–95.PubMedCrossRefGoogle Scholar
  91. Shah, A. S., White, D. C., Emani, S., Kypson, A. P., Lilly, R. E., Wilson, K., Glower, D. D., Lefkowitz, R. J., and Koch, W J. (2001). In vivo ventricular gene delivery of a β-ad-renergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 103, 1311–6.PubMedCrossRefGoogle Scholar
  92. Simpson, P. (1983). Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an α1 adrenergic response. J Clin Invest 72, 732–8.PubMedCrossRefGoogle Scholar
  93. Subramaniam, A., Jones, W K., Gulick, J., Wert, S., Neumann, J., and Robbins, J. (1991). Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 266, 24613–20.PubMedGoogle Scholar
  94. Sugden, P. H. (2001). Signalling pathways in cardiac myocyte hypertrophy. Ann Med 33, 611–22.PubMedGoogle Scholar
  95. Tepe, N. M., Lorenz, J. N., Yatani, A., Dash, R., Kranias, E. G., Dorn, G. W., 2nd, and Liggett, S. B. (1999). Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte β-adrenergic signalling. Biochemistry 38, 16706–13.PubMedCrossRefGoogle Scholar
  96. Towbin, J. A., and Bowles, N. E. (2002). The failing heart. Nature 415, 227–33.PubMedCrossRefGoogle Scholar
  97. Ungerer, M., Bohm, M., Elce, J. S., Erdmann, E., and Lohse, M. J. (1993). Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart [see comments]. Circulation 87, 454–63.PubMedCrossRefGoogle Scholar
  98. Ungerer, M., Parruti, G., Bohm, M., Puzicha, M., DeBlasi, A., Erdmann, E., and Lohse, M. J. (1994). Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart. Circ Res 74, 206–13.PubMedCrossRefGoogle Scholar
  99. Ungerer, M., Kessebohm, K., Kronsbein, K., Lohse, M. J., and Richardt, G. (1996). Activation of β-adrenergic receptor kinase during myocardial ischemia. Circ Res 79, 455–60.PubMedCrossRefGoogle Scholar
  100. White, D. C., Hata, J. A., Shah, A. S., Glower, D. D., Lefkowitz, R. J., and Koch, W J. (2000). Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA 97, 5428–33.PubMedCrossRefGoogle Scholar
  101. Xiao, R. P., Avdonin, P., Zhou, Y. Y., Cheng, H., Akhter, S. A., Eschenhagen, T., Lefkowitz, R. J., Koch, W. J., and Lakatta, E. G. (1999). Coupling of β2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84, 43–52.PubMedCrossRefGoogle Scholar
  102. Zhu, W. Z., Zheng, M., Koch, W J., Lefkowitz, R. J., Kobilka, B. K., and Xiao, R. P. (2001). Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98, 1607–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • W. J. Koch
    • 1
  • B. C. Blaxall
    • 2
  1. 1.Department of SurgeryDuke University Medical CenterDurhamUSA
  2. 2.Division of CardiologyCenter for Cellular and Molecular Cardiology University of Rochester Medical CenterRochesterUSA

Personalised recommendations